Agenus | AGEN - Ordinary Share Capital


Agenus reported $266K in Ordinary Share Capital for its fiscal quarter ending in March of 2025.





Ordinary Share Capital Change Date
AbbVie USD 1.77B 1.75B Jun/2025
Agenus USD 266K 30K Mar/2025
Amgen USD 539M 1000K Dec/2025
AstraZeneca USD 1.55B 206K Dec/2025
Bristol-Myers Squibb USD 2.04B 1.74B Sep/2025
Celldex Therapeutics USD 66.45M 53K Sep/2025
CSL USD 576M 19M Dec/2024
Dynavax Technologies USD 117.23M 117.11M Jun/2025
Eli Lilly USD 946.83M 354.23M Jun/2025
Gilead Sciences USD 1.24B 1000K Dec/2025
GlaxoSmithKline GBP 4.08B 49.43M Dec/2025
Glaxosmithkline GBP 4.03B 2.68B Sep/2025
Incyte USD 196.13M 2.01M Sep/2025
Intrexon USD 0 0 Jun/2024
J&J USD 2.41B 584K Sep/2025
Jiangsu Hengrui CNY 6.64B 0 Sep/2025
Karyopharm Therapeutics USD 13K 0 Sep/2024
MacroGenics USD 63.26M 62.63M Sep/2025
Merck EUR 434.78M 130.22M Jun/2025
Merck USD 2.49B 15.79M Sep/2025
Novartis USD 1.94B 23.4M Jun/2025
Novavax USD 1.62M 211K Sep/2024
Pfizer USD 5.69B 1000K Sep/2025
Regeneron Pharmaceuticals USD 105.3M 1.1M Sep/2025
Rigel Pharmaceuticals USD 17K 158K Jun/2024
Veracyte USD 78.67M 73K Sep/2025